| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $38,140,513 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM148326 | Center of Biomedical Research Excellence in CNS Metabolism | 000 | 4 | NIH | 2/27/2026 | $2,102,000 |
| | 2026 | 2026 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T9952106 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $1,175,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL172844 | Mechanisms of Thrombosis in SARS CoV-2 Infection | 001 | 2 | NIH | 3/27/2026 | $14,103 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140312 | Targeting Intracellular Cholesterol Distribution: Mechanisms and Therapeutic Strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/11/2026 | $707,062 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098743 | Arginine Sensor (CASTOR1) Dysfunction Drives Tauopathy | 000 | 1 | NIH | 1/21/2026 | $423,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG081608 | Molecular genetics of human age-related hearing loss | 001 | 4 | NIH | 3/10/2026 | $587,270 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG070279 | Cognitive Aging Trajectories in Survivors of Trauma | 000 | 4 | NIH | 3/9/2026 | $125,626 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 001 | 3 | NIH | 2/26/2026 | $65,020 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093847 | Lactate as a regulator of Alzheimer's pathology | 000 | 2 | NIH | 3/9/2026 | $747,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R13DC016831 | International Society for Neurogastronomy Symposium | 000 | 9 | NIH | 3/10/2026 | $1 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI197062 | Switches controlling bacteriophage lysis of the Lyme disease spirochete | 000 | 1 | NIH | 2/18/2026 | $420,063 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35HL150818 | Platelet Exocytosis and Endocytosis in Thrombosis and Immunity | 000 | 7 | NIH | 3/2/2026 | $884,606 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL170972 | Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction | 000 | 3 | NIH | 2/25/2026 | $35,530 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG080589 | APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease | 001 | 4 | NIH | 2/23/2026 | $64,226 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 3 | NIH | 2/27/2026 | $402,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG090534 | Blood-Brain Barrier Dysfunction in Alzheimer’s Disease: New Mechanistic Insights and Therapeutic Strategies | 001 | 2 | NIH | 2/24/2026 | $71,324 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 5 | NIH | 3/2/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00HG011657 | Analysis of Somatic Mutations in Longitudinal Whole-genome Sequencing Data | 000 | 5 | NIH | 3/2/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61DA064790 | Support Towards Addiction Recovery for Individuals with Criminal Legal System Involvement: The STAR Project | 000 | 1 | NIH | 2/24/2026 | $422,921 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 000 | 4 | NIH | 2/23/2026 | $631,720 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124626 | Mechanisms for activation of beige adipose tissue in humans | 000 | 5 | NIH | 1/13/2026 | $448,041 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 001 | 4 | NIH | 2/23/2026 | $65,188 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 000 | 4 | NIH | 12/22/2025 | $586,701 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31AG087618 | Using the gut microbiome to treat disuse atrophy in aging. | 000 | 2 | NIH | 1/14/2026 | $44,495 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 2 | NIH | 1/16/2026 | $399,502 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA301113 | Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer | 000 | 2 | NIH | 4/2/2026 | $215,985 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK131786 | Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease | 000 | 5 | NIH | 4/28/2026 | $478,167 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21HD117520 | Evaluating causes for failure to thrive in a Noonan-like syndrome with loose anagen hair (NSLH) patients using NSLH vertebrate model | 001 | 2 | NIH | 4/2/2026 | $19,250 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 3 | NIH | 4/27/2026 | $643,810 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI165521 | Novel antiviral mechanisms of the interferon system | 000 | 5 | NIH | 4/24/2026 | $416,425 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM152104 | Obesity-mediated protection in sepsis | 000 | 3 | NIH | 4/24/2026 | $380,742 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140148 | Role of Hypothalamic Adgrl1 in Counteracting Hypoglycemia | 000 | 2 | NIH | 4/13/2026 | $480,373 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K22HL171175 | Transgelin Differentially Modulates the Uptake of LDL in Hepatocytes and Smooth Muscle Cells: A New Gene Involved in LDL Clearance and Atherosclerosis. | 000 | 1 | NIH | 4/28/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 000 | 2 | NIH | 3/26/2026 | $515,737 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 001 | 4 | NIH | 3/26/2026 | $19,950 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31AG087618 | Using the gut microbiome to treat disuse atrophy in aging. | 001 | 2 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AA030775 | Influence of Orexin Antagonism on Motivation for Alcohol | 000 | 3 | NIH | 3/24/2026 | $511,222 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01MH134859 | Neural Mechanisms of Menstrual Cycle Effects on ADHD and Cognition | 000 | 3 | NIH | 4/21/2026 | $736,038 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA058933 | Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal | 000 | 4 | NIH | 4/29/2026 | $487,408 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 002 | 2 | NIH | 4/29/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | H3H00046 | SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM | 00 | 25 | HRSA | 4/21/2026 | $660,865 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32AA027488 | Interdisciplinary Training in Alcohol Research | 000 | 8 | NIH | 4/21/2026 | $172,616 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | H7600719 | Ryan White Part C Outpatient EIS Program | 00 | 25 | HRSA | 3/25/2026 | $108,332 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA064646 | Evaluation of the Combination Muscarinic Cholinergic Receptor Drug Product Cobenfy as a Medication for Cocaine Use Disorder Using Translational Human and Rat Cocaine Choice Procedures | 000 | 1 | NIH | 5/1/2026 | $663,978 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 001 | 2 | NIH | 4/27/2026 | $2,048 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 000 | 2 | NIH | 4/3/2026 | $522,854 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098189 | Decoding the Muscle Epitranscriptome: Deep Learning Detection of RNA Modifications in Aging Muscle | 000 | 1 | NIH | 1/21/2026 | $616,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01GM150200 | Study of PTPRF-Mediated Regulation of Wnt Signaling | 000 | 4 | NIH | 4/3/2026 | $347,125 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM121327 | University of Kentucky Center for Cancer Metabolism | 001 | 10 | NIH | 3/11/2026 | $228,965 |
|
